Swiss drugmaker Novartis on Friday won a key European recommendation for its gene therapy Zolgensma against spinal muscular atrophy (SMA), clearing a hurdle for $2.1 million per patient treatment for approval in Europe within months. The European Medicines Agency's (EMA) Committee for Human Medicines...

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of......

Global events, meetings and symposiums are being canceled in droves as a precautionary measure to help contain the coronavirus pandemic. Biogen Inc (NASDAQ: BIIB) executives attended a conference sponsored by Cowen in Boston last month have become responsible for most cases of COVID-19 in Massachusetts...

U.S. drugmaker Biogen Inc said on Wednesday that some patients on its drug Spinraza - which treats a rare disorder called spinal muscular atrophy (SMA) - are having their treatments postponed to prioritize COVID-19 patients. Biogen did not give further details about how many patients were having their...

Biogen Inc. (BIIB) today announced that the Biogen Foundation has committed $10 million to support global response efforts and communities around the world impacted by the COVID-19 pandemic. The funds will be used to address immediate critical needs, with the majority of donations going to support non-profit...

The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.Biogen Inc (NASDAQ: BIIB) was in the news for all wrong reasons, as an employee conference held by the company in Boston from Feb. 24 to 27 was blamed for 77 of the 95 COVID-19 cases reported...

The decision is based on "new information," Marriott International said in a statement Thursday....

(Bloomberg) -- At the Northeastern University Emergent Epidemics Lab, researchers have a convenient petri dish for studying the spread of pandemics: their hometown of Boston.The city is one of the major coronavirus clusters in the U.S., along with Westchester County, New York, and Seattle. In Boston,...

The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway...

Shares of Vir Biotechnology Inc. gained 15% in premarket trading on Thursday after it said it intends to partner with Biogen Inc. to help develop and manufacture its monoclonal antibodies as a potential treatment of COVID-19. Biogen will handle clinical manufacturing of Vir's antibodies, the company said. Biogen's stock is down 3%. Vir, a startup biotechnology company founded in 2016, had previously announced plans to collaborate with Shanghai-based WuXi Biologics to test the antibodies as a treatment for the novel coronavirus. Vir CEO George Scangos previously was the chief executive of Biogen, which is facing COVID-19 cases of its own, after a cluster of infections emerged from a management meeting it held at a hotel in Boston in late February. All of its employees are working from home, as a result. Year-to-date, Vir's stock is up 168%, while shares of Biogen are down 0.8%. The S&P 500 is down 15% year-to-date....